Results 41 to 50 of about 3,373 (135)

Evaluation of Discontinuation and Re‐Initiation of Biologic Therapies in Psoriasis: Real‐World Data

International Journal of Dermatology, EarlyView.
The cumulative probability of remaining relapse‐free following biologic therapy discontinuation was 35.6%, 19%, 11.6%, and 9.1% at 6, 12, 18, and 24 months, respectively. Prolonged relapse durations were associated with a low baseline PASI score, the presence of a PASI 90 response at discontinuation, the absence of triggering factors, and the use of IL‐
Ahmet Taha Aydemir, Nihal Kundakcı
wiley   +1 more source

Annular pustular crusted plaques as unusual cutaneous presentation of systemic lupus erythematosus

Clinical Case Reports, 2023
Key Clinical Message Systemic lupus erythematosus (SLE) is a systemic autoimmune disease that affects several organs including the skin. Clinical cutaneous symptoms of SLE come in a broad range, consisting of both non‐specific and specific cutaneous ...
Mehdi Gheisari, Moein Baghani, Raziyeh Ganji, Khatere Zahedi   +3 more
doaj   +1 more source

Deep and disseminated dermatophytosis in immunocompromised populations—A systematic review

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Dermatophyte infections of the dermis and subcutaneous tissue (i.e. deep dermatophytosis)—associated with secondary complications including pseudomycetoma and systemic dissemination—affect vulnerable populations with primary or acquired immunodeficiencies.
Aditya K. Gupta, Tong Wang, Susmita, Ditte Marie L. Saunte, Roderick Hay, Vincent Piguet   +5 more
wiley   +1 more source

Sustained Remission of Pediatric Bowel‐Associated Dermatosis‐Arthritis Syndrome With Risankizumab

Pediatric Dermatology, EarlyView.
ABSTRACT Bowel‐associated dermatosis‐arthritis syndrome (BADAS) is a rare neutrophilic dermatosis characterized by recurrent fever, arthralgias, and skin eruptions, most commonly occurring in patients with inflammatory bowel disease. We report the case of a 17‐year‐old female with Crohn's disease who developed BADAS and achieved complete and durable ...
Kylie E. Peake, Harman Toor, Marie‐Christine Jean, Collin C. Barker, Joseph M. Lam   +4 more
wiley   +1 more source

A Case of Annular Pustular Psoriasis Possibly Triggered by Cabozantinib and Edoxaban During Nivolumab Therapy

The Journal of Dermatology, EarlyView.
Mana Nagatake, Hiroto Horikawa, Risa Kakuta, Takeya Adachi, Keishiro Fukumoto, Masayuki Amagai, Yoshihiro Ito   +6 more
wiley   +1 more source

Carbon Footprint of Antibody‐Based Drugs and Biologics Using Hybrid Life Cycle Assessment

Clinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 236-244, July 2026.
Life cycle assessment of monoclonal antibodies. Biological engineering has emerged since the 1980s as one of the most efficient technologies to develop new medicines. The monoclonal antibody platform is the most widely used, representing about 15–20% of drug sales.
Sébastien Taillemite, Martin Fenelon, Marc Scherlinger, Max Piffoux   +3 more
wiley   +1 more source

Diagnostic concordance of dermatopathology and PCR in differentiating eczema from psoriasis

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 7, Page 1227-1237, July 2026.
Distinguishing psoriasis from eczema is challenging due to overlapping clinical and histological features. This study shows substantial inter‐observer variability among dermatopathologists and demonstrates that a NOS2‐/CCL27‐based molecular test, including a fully automated platform, provides more accurate and reproducible diagnoses, particularly in ...
Andrea Schmitt, Susanne Proksch, Ludwig Gutzweiler, Sandra Roth, Marcella Engler, Cornelia S. L. Müller, Andreas Volz, Andreas W. Arnold, Monika Šedivcová, Adriana Bernklauova, Miroslav Dura, Denisa Kacerovska, Katja Technau‐Ihling, Christian Ihling, Christiane Rakozy, Wiebke Pruessmann, Thomas Leibing, Maria Isabel von Eichborn, Johannes Kern, Elisabeth Oms, Stefanie Eyerich, Kilian Eyerich, Helmut Laaff, Natalie Garzorz‐Stark, Kristin Technau‐Hafsi   +24 more
wiley   +1 more source

Successful Use of Bimekizumab in Refractory Acute Generalised Exanthematous Pustulosis Triggered by Amoxicillin‐Clavulanate

JEADV Clinical Practice, Volume 5, Issue 2, Page 669-672, June 2026.
ABSTRACT Acute generalised exanthematous pustulosis (AGEP) is a rare, acute neutrophilic dermatosis most commonly triggered by drugs, which typically resolves within 2 weeks following withdrawal of the causative agent. Topical and systemic corticosteroids remain the standard treatment.
Alexandra Junge, Charlotte Vogel, Theresa Hempel, Basil Signer, Nikhil Yawalkar, Kristine Heidemeyer   +5 more
wiley   +1 more source

Diagnosis and screening of patients with generalized pustular psoriasis

Psoriasis: Targets and Therapy, 2019
Karen Ly,* Kristen M Beck*, Mary P Smith, Quinn Thibodeaux, Tina BhutaniDepartment of Dermatology, University of California, San Francisco, CA, USA*These authors contributed equally to this work Abstract: Generalized pustular psoriasis (GPP) is a rare ...
Ly K, Beck KM, Smith MP, Thibodeaux Q, Bhutani T   +4 more
doaj  

New Biologic and Small Molecule Therapies for Hidradenitis Suppurativa

JEADV Clinical Practice, Volume 5, Issue 2, Page 373-384, June 2026.
ABSTRACT Hidradenitis suppurativa (HS) is an inflammatory skin disease that has historically been underdiagnosed and, until recently, under‐researched. Furthermore, the pathophysiology of HS is complex, and not fully understood. Just three biologic medications—adalimumab (anti‐TNF‐α), secukinumab (anti‐IL17A) and bimekizumab (anti‐IL17A/F) are licensed
Emily Pender, Rosalind Hughes, Brian Kirby   +2 more
wiley   +1 more source